Related Announcements

PA-20-183- Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-194- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PA-20-195- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

PA-20-196- NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

PA-20-272- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

NOT-MD-22-006- Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

NIDA seeks to support research in addressing SARS-CoV-2 vaccine implementation among populations with current substance use and substance use disorders, particularly those from NIH-designated U.S. health disparity populations (see a full description at https://www.nimhd.nih.gov/about/overview/). Additionally, NIDA is interested in research on understanding and increasing engagement in clinical trials investigating the efficacy of vaccines for substance use disorder (SUD) among health disparity populations.

Areas of special interest include but are not limited to the following:

• Effective ways to vaccinate and/or provide boosters to substance using adults and adolescents, substance using pregnant people, and the children of substance using parents who are not currently engaged in treatment
• Effective ways to mobilize community resources (e.g., community organizations, social networks) to increase vaccine delivery to individuals with substance use disorder who are experiencing homelessness or who are marginally housed
• Increased understanding of how models for outreach to and engagement of individuals with substance use disorder (e.g., peer navigators, peer educators, peer recovery coaches, mobile outreach services) can be adapted for implementing SARS-CoV-2 vaccination in similar populations
• Implications of vaccine mandates for substance using populations
• Increased understanding of how stigma and misinformation serve as barriers to receipt of SARS-CoV-2 and SUD vaccinations, and strategies for addressing these barriers
• Approaches for encouraging widespread vaccination among persons who are in treatment for substance use disorders
• Increased understanding of the representation of health disparity populations in SUD vaccine trials
• Increased understanding of health disparity populations’ attitudes about and interest in participating in SUD vaccine clinical trials
• Improved understanding of barriers that health disparity populations face when accessing SUD vaccines
• Strategies to increase access to SUD vaccines for health disparity populations

Inquiries

Please direct all inquiries to:

Grants Management Contact

Pam Fleming

National Institute on Drug Abuse

Telephone: 301-480-1159

Email: pfleming@mail.nih.gov

Scientific/Research Contacts

Julia Zur, Ph.D.

Division of Epidemiology, Prevention, and Services Research

National Institute on Drug Abuse (NIDA)

Telephone: 301-443-2261

Email: julia.zur@nih.gov